Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Terry D. who wrote (2485)	8/29/1998 7:51:00 AM
From: Tim K	Read Replies (1) \| Respond to of 3702

Yesterday's TCLN news release was great news, but there will be more news coming from this Phase I. I went back to the July 21 news release concerning the amended protocol for the Phase I and found this..... "The amended dosing protocol is patient specific, is based on the volume of the brain tumor observed, and on delivering a single dose of approximately 15,000 rads of radiation to the primary tumor. Under the amended protocol, the remaining patients (estimated at 6-9) in this Phase I trial will be treated with the new individual dosing regimen." I eMailed TCLN yesterday to ask if this was still the plan and the response was that the current Phase I will include testing with the 15,000 rad dose. Apparently we won't have to wait for the Phase II to see results from the higher dose regimen. If the results show significant success and safety at the higher dosage, Nov. 12 could be an historic day for TCLN and my vacation plans!